Education and Training

Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (Tweet2Quit)

Tweet2Quit is an innovative smoking cessation intervention that combines real-time online peer-to-peer support with auto messaging. In a three-group randomized controlled trial, the investigators will compare: 1) usual care, 2) Tweet2Quit-coed, and 3) Tweet2Quit-Women only.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • drug: NRT
  • behavioral: Web Guide
  • behavioral: Tweet2Quit

Eligibility


Inclusion Criteria:

   - Are 21-59 years of age

   - Are smoking 5+ cigarettes/day and 100+ cigarettes in one's lifetime

   - In the preparation stage of quitting smoking

   - Are English speaking

   - Have a mobile phone with an unlimited texting plan and internet access (via mobile
   phone)

   - Text at least once a week

   - Are a social media user

   - Have an active email account

   - Lives in the continental USA

Exclusion Criteria:

   - Have certain medical conditions that are contraindicated for nicotine replacement
   therapy: pregnant, breast feeding, a recent heart attack, an irregular heartbeat, high
   blood pressure not controlled with medication, skin allergies to adhesive tape or
   serious skin problems, taking a prescription medicine for depression, and/or any other
   medical conditions that would prevent you from completing this study.

   - Are an illicit hard drug user or regular marijuana user

   - Share a household with someone else or has an immediate family member who has already
   enrolled in the study currently or in the past or if the participant has already been
   enrolled or failed to pass the screening once already since October 2016

   - Participated in Tweet2Quit between 2012-2013 in a Twitter group and was not an active
   tweeter (<1 week)

   - Fails to provide valid forms of all the required personal contact information

Ages Eligible for Study

21 Years - 59 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Judith J Prochaska, PhD, MPH
650-724-3608
Not Recruiting